应用基因重组Epstein-Barr病毒早期抗原P83蛋白检测鼻咽癌患者血清中的IgA/EA抗体

将pUCB质粒表达的P83蛋白应用于免疫印迹法(IB)和ELISA中,检测了85例鼻咽癌(NPC)患者和100例健康人血清,同时与免疫酶法(IE)作比较。结果表明,免疫印迹法对NPC患者血清阳性检出率为94％;ELISA法阳性检出率为88％;而IE法阳性率为64％。三种方法检测健康人血清出现低水平IgA/EA抗体的阳性率分别为4％、3％及2％。用IE法检测IgA/EA抗体为阴性的NPC患者血清,用IB法检测的阳性率达87％,ELISA法阳性检出率为77％。IB法与ELISA法之间具有较好的正相关(r=0.67,P<0.01)。

DETECTION OF IGA/EA ANTIBODY IN SERA FROM NASOPHARYNGEAL CARCINOMA PATIENTS BY RECOMBINANT P83 PROTEIN OF EPSTEIN-BARR VIRUS

New immunoblot ( IB ) and ELISA tests have been developed with recombinant P83 fusion protein of Epstein-Barr virus. In immunoblot test P83 fusion protein was transferred into nitrocellulose with the We-stern blot method. The recombinant P83 fusion protein was purified by SDS-PAGE. The recombinant P83 fusion protein was used to detect IgA antibody against EA of EB virus in the sera from NPC patients by IB, ELISA and immunoenzymatic ( IE ) test. Sera from 85 NPC patients and 100 normai individuals were tested. The IgA/EA antibody-positive rates were 94%, 88%,and 64%,by IB, ELISA,and IE respectively in NPC patie nts,while 4%,3%,and 2% were positive by IB,ELISA,and IE respectively in 100 normai individuals. Among the NPC patients with negative IgA/EA antibody detected by IE,IgA/EA antibody positive rates were 87%, and 77% respectively by IB,and ELISA. There was a good correlation (r = 0.67, P<0.01) between the value of IB and mean value ( P/N ) of ELISA. The authors conclude that IB and ELISA with recombinant P83 fusion protein as antigen are more sensitive and specific than IE test, and are useful in the mass survey for NPC patients.